The Center for Biosimilars® recaps the top stories for the week of September 2, 2019.
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 2, 2019.
Number 5: At Amgen’s request, the Patent Trial and Appeal Board will review several key patents on Alexion’s Soliris.
Number 4: Canada’s regulatory body recently updated its fact sheet on biosimilars, including new or clarified information about key topics such as switching.
Number 3: England’s National Health Service says that it has saved the equivalent of $134 million on adalimumab after Humira lost patent protection in 2018.
Number 2: The FDA has given Mylan and Biocon a second Complete Response Letter for their follow-on insulin glargine.
Number 1: Biosimilars for multiple sclerosis drugs are now on the horizon after Sandoz announced its plan to commercialize a biosimilar natalizumab.
Finally, last week, our e-newsletter asked whether you agree with a new treatment guideline that recommends that stable patients not be required to switch to biosimilars.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.